great example is impax labs, FDA has fined them for mfg'ing deficiencies which has delayed their new sinemet cr from being approved by at least a year.

unfortunately stockholders are forcing drug companies to raise prices and/or get out of generics and chinese/indian/etc. mfgs at times cut corners and lowball prices which speeds up the better generic mfg's to unload less profitable drugs.

seems like it's only going to get worse.